Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Marinus Pharmaceuticals (MRNS) stock

Learn how to easily invest in Marinus Pharmaceuticals stock.

Marinus Pharmaceuticals, Inc
NASDAQ: MRNS - USD
BIOTECHNOLOGY
$17.90
-$1.07 (-5.64%)

Marinus Pharmaceuticals, Inc is a biotechnology business based in the US. Marinus Pharmaceuticals shares (MRNS) are listed on the NASDAQ and all prices are listed in US Dollars. Marinus Pharmaceuticals employs 82 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Marinus Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MRNS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Marinus Pharmaceuticals stock price (NASDAQ: MRNS)

Use our graph to track the performance of MRNS stocks over time.

Marinus Pharmaceuticals shares at a glance

Information last updated 2021-07-08.
Latest market close$16.82
52-week range$6.04 - $20.04
50-day moving average $17.77
200-day moving average $15.22
Wall St. target price$29.56
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.98

Buy Marinus Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
$0 per year
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Marinus Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Marinus Pharmaceuticals price performance over time

Historical closes compared with the close of $16.82 from 2021-05-28

1 week (2021-07-01) -10.05%
1 month (2021-06-08) N/A
3 months (2021-04-12) 20.23%
6 months (2021-01-12) 38.55%
1 year (2020-07-10) 621.89%
2 years (2019-07-12) 267.25%
3 years (2018-07-12) 115.92%
5 years (2016-07-12) 985.16%

Marinus Pharmaceuticals financials

Revenue TTM $3.5 million
Gross profit TTM $-45,850,000
Return on assets TTM -43.63%
Return on equity TTM -81.38%
Profit margin 0%
Book value $3.03
Market capitalisation $689.9 million

TTM: trailing 12 months

Shorting Marinus Pharmaceuticals shares

There are currently 4.1 million Marinus Pharmaceuticals shares held short by investors – that's known as Marinus Pharmaceuticals's "short interest". This figure is 6.8% down from 4.4 million last month.

There are a few different ways that this level of interest in shorting Marinus Pharmaceuticals shares can be evaluated.

Marinus Pharmaceuticals's "short interest ratio" (SIR)

Marinus Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Marinus Pharmaceuticals shares currently shorted divided by the average quantity of Marinus Pharmaceuticals shares traded daily (recently around 213856.592827). Marinus Pharmaceuticals's SIR currently stands at 18.96. In other words for every 100,000 Marinus Pharmaceuticals shares traded daily on the market, roughly 18960 shares are currently held short.

However Marinus Pharmaceuticals's short interest can also be evaluated against the total number of Marinus Pharmaceuticals shares, or, against the total number of tradable Marinus Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Marinus Pharmaceuticals's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 Marinus Pharmaceuticals shares in existence, roughly 110 shares are currently held short) or 0.1779% of the tradable shares (for every 100,000 tradable Marinus Pharmaceuticals shares, roughly 178 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Marinus Pharmaceuticals.

Find out more about how you can short Marinus Pharmaceuticals stock.

Marinus Pharmaceuticals share dividends

We're not expecting Marinus Pharmaceuticals to pay a dividend over the next 12 months.

Have Marinus Pharmaceuticals's shares ever split?

Marinus Pharmaceuticals's shares were split on a 1:4 basis on 22 September 2020. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Marinus Pharmaceuticals shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Marinus Pharmaceuticals shares which in turn could have impacted Marinus Pharmaceuticals's share price.

Marinus Pharmaceuticals share price volatility

Over the last 12 months, Marinus Pharmaceuticals's shares have ranged in value from as little as $6.04 up to $20.04. A popular way to gauge a stock's volatility is its "beta".

MRNS.US volatility(beta: 1.4)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Marinus Pharmaceuticals's is 1.4049. This would suggest that Marinus Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Marinus Pharmaceuticals overview

Marinus Pharmaceuticals, Inc. , a clinical stage pharmaceutical company, focuses on developing and commercializing therapeutics to treat rare seizure disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in formulations for two routes, including intravenous (IV) and oral for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ganaxolone product candidate, acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for status epilepticus, cyclin dependent kinase like 5 deficiency disorder, PCDH19-related epilepsy, tuberous sclerosis complex, and postpartum depression. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.

Frequently asked questions

What percentage of Marinus Pharmaceuticals is owned by insiders or institutions?
Currently 0.139% of Marinus Pharmaceuticals shares are held by insiders and 87.545% by institutions.
How many people work for Marinus Pharmaceuticals?
Latest data suggests 82 work at Marinus Pharmaceuticals.
When does the fiscal year end for Marinus Pharmaceuticals?
Marinus Pharmaceuticals's fiscal year ends in December.
Where is Marinus Pharmaceuticals based?
Marinus Pharmaceuticals's address is: 5 Radnor Corporate Center, Radnor, PA, United States, 19087
What is Marinus Pharmaceuticals's ISIN number?
Marinus Pharmaceuticals's international securities identification number is: US56854Q2003
What is Marinus Pharmaceuticals's CUSIP number?
Marinus Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 56854Q101

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site